StockMirror — Stock Screener

HCG Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

HCG reported a strong Q2 FY27 with 16% YoY revenue growth and 17% YoY EBITDA growth, driven by a 9% volume increase and 7% ARPP improvement from a richer procedure mix. EBITDA margins expanded by 50 bps YoY despite a one-time INR 60 million wage cost impact. The company is on track with its mid-teens revenue and high-teens EBITDA growth guidance. The primary investor concern was the new regulatory trade margin cap on oncology drugs, which is expected to cause a mid-to-high single-digit annualized EBITDA hit, effective from Q3. Management is confident in mitigating this impact through various operational levers and remains positive on the long-term growth outlook.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

The company's strategy is centered on 'profitable growth.' Management highlighted that they are achieving revenue growth while simultaneously expanding margins by improving revenue mix (more complex procedures, better payor mix) and driving operating efficiencies. They also stated their guidance is

About HealthCare Global Enterprises Limited

HealthCare Global Enterprises Limited (HCG) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More